However, the potential antiinflammatory effects of GLP-1 signaling in the central nervous system, lungs, and intestine remain to be fully elucidated and warrant further investigation
Whilst the market is currently led by Novo Nordisks semaglutide (Ozempic/Wegovy) and Eli Lillys tirzepatide (Mounjaro/Zepbound), stronger competition is expected with new entrants (Boehringer Ingelheim, Amgen, Pfizer, Roche amongst others) offering novel mechanisms (dual agonists, triple agonists and amylins), formulations (oral vs injectable) and dosing regimens (daily vs weekly vs monthly).
Drivers : Strong growth of private label and OEM services for brands
GLP-1 medications like semaglutide have transformed weight management for millions, but breastfeeding introduces critical safety questions that deserve thorough, evidence-based answers
Always consult a physician
What we tell patients If you are struggling with nausea, fatigue, or other side effects on a GLP-1 medication, please contact us before stopping treatment